Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MIRM 
Mirum Pharmaceuticals Inc (MIRM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: MIRM (4-star) is a STRONG-BUY. BUY since 83 days. Simulated Profits (61.31%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $79.6
1 Year Target Price $79.6
| 6 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 63.54% | Avg. Invested days 43 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.71B USD | Price to earnings Ratio - | 1Y Target Price 79.6 |
Price to earnings Ratio - | 1Y Target Price 79.6 | ||
Volume (30-day avg) 10 | Beta 0.93 | 52 Weeks Range 36.88 - 78.09 | Updated Date 09/17/2025 |
52 Weeks Range 36.88 - 78.09 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -13.65% | Operating Margin (TTM) -3.9% |
Management Effectiveness
Return on Assets (TTM) -5.15% | Return on Equity (TTM) -24.19% |
Valuation
Trailing PE - | Forward PE 39.68 | Enterprise Value 3741477030 | Price to Sales(TTM) 8.64 |
Enterprise Value 3741477030 | Price to Sales(TTM) 8.64 | ||
Enterprise Value to Revenue 8.72 | Enterprise Value to EBITDA -8.85 | Shares Outstanding 50237600 | Shares Floating 39977110 |
Shares Outstanding 50237600 | Shares Floating 39977110 | ||
Percent Insiders 1.86 | Percent Institutions 114.07 |
Upturn AI SWOT
Mirum Pharmaceuticals Inc
Company Overview
History and Background
Mirum Pharmaceuticals Inc. was founded in 2018. It focuses on developing and commercializing novel therapies for debilitating liver diseases.
Core Business Areas
- Hepatobiliary Diseases: Focuses on the development and commercialization of therapies for rare and severe liver diseases, particularly those affecting children.
Leadership and Structure
The leadership team includes executives with experience in the pharmaceutical industry. The organizational structure is typical of a biotechnology company, with departments focused on research and development, clinical trials, commercialization, and corporate functions.
Top Products and Market Share
Key Offerings
- LIVMARLI (maralixibat): LIVMARLI is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) aged three months and older. The competitors are off-label treatments and potential future therapies from other companies. Revenue from LIVMARLI in 2023 was approximately $134.4 million.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the segment focused on rare liver diseases, is characterized by high barriers to entry, orphan drug designations, and significant unmet medical needs.
Positioning
Mirum is positioned as a leader in developing therapies for rare cholestatic liver diseases, particularly in pediatric populations. Its competitive advantage lies in its focused approach and established presence in the ALGS market.
Total Addressable Market (TAM)
The TAM for rare liver diseases is substantial and growing, driven by increasing diagnosis rates and the development of new therapies. Mirum is positioned to capture a significant portion of this market, especially with the potential expansion of LIVMARLI to other indications.
Upturn SWOT Analysis
Strengths
- FDA-approved product (LIVMARLI)
- Strong focus on rare liver diseases
- Experienced management team
- Orphan drug designation
Weaknesses
- Reliance on a single product (LIVMARLI)
- Limited commercial infrastructure
- High R&D expenses
- Potential competition from larger pharmaceutical companies
Opportunities
- Expansion of LIVMARLI to other indications (e.g., progressive familial intrahepatic cholestasis (PFIC))
- Development of new therapies for other rare liver diseases
- Partnerships and collaborations with other companies
- Geographic expansion
Threats
- Competition from existing therapies and new entrants
- Regulatory hurdles and changes
- Clinical trial failures
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- ALNY
- ICPT
- GOVX
Competitive Landscape
Mirum competes with companies developing therapies for liver diseases, including larger pharmaceutical companies with broader portfolios. Mirum's competitive advantage lies in its focus on rare cholestatic liver diseases.
Major Acquisitions
u0995u09b0u09c7u09a8u09bf
- Year: 2021
- Acquisition Price (USD millions): 48
- Strategic Rationale: Acquisition of gene therapy assets for liver diseases.
Growth Trajectory and Initiatives
Historical Growth: Mirum has experienced significant revenue growth since the launch of LIVMARLI.
Future Projections: Analysts project continued revenue growth driven by LIVMARLI sales and potential expansion to other indications. Profitability is expected to improve in the coming years.
Recent Initiatives: Recent initiatives include ongoing clinical trials for LIVMARLI in other indications and the development of new therapies for other rare liver diseases.
Summary
Mirum Pharmaceuticals is focused on developing liver disease treatments, with Livmarli being its primary revenue source. While revenue is growing, it's also burning cash. Mirum needs to effectively manage cash usage and pipeline development, and should watch out for competition and regulation changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mirum Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 2019-07-18 | CEO & Director Mr. Christopher Peetz | ||
Sector Healthcare | Industry Biotechnology | Full time employees 349 | Website https://www.mirumpharma.com |
Full time employees 349 | Website https://www.mirumpharma.com | ||
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.